Russian markets are down 1.4% today, after losing World War 3 to America this past weekend. Our futures are +140. It just so happens I am completely long, aside from my ‘fuck Russia’ trade — long RUSS — which is a play on betting against the GIGANTIC slavic nation of ice people.
Fun fact about Russia: back in the 1200s, the Mongols conquered them and are the reason why the entire land mass eventually united. Also, the Russian royal family is said to have ~15% mongol blood in them, from all of the cross-breeding done between the two people’s when the Golden Horde ruled over them.
Oil is -1.2%, probably because of lack of happenings in the Middle East. We were hoping to rope both Iran and Russia into armed conflict, which would’ve killed scores, but also have been boolish for WTI and Brent.
European markets are lower, most likely due to the fact that Russia might decide to freeze the entire continent to death next winter. But I suppose we’ll cross that bridge when we get there.
This could be viewed as dovish.
Russia and China are playing the Currency Devaluation game as the U.S. keeps raising interest rates. Not acceptable!
— Donald J. Trump (@realDonaldTrump) April 16, 2018
And then there’s this.
Who is the best war time POTUS of all time?
— The_Real_Fly (@The_Real_Fly) April 15, 2018
Here are the other headlines littering my fucking screen right now.
In reaction to strong earnings/guidance:
- BAC +1.0%
- ERI +7.3% (to acquire Tropicana Entertainment (TPCA) in a cash transaction that is valued at $1.85 bln)
- IEP +1.7% (confirms agreement to sell Tropicana’s real estate to Gaming and Leisure Properties)
- ALKS +18.7% (announces that the FDA has accepted for review the NDA for ALKS 5461)
- ACRX +8.9% (announced the successful completion of the human factors (HF) study performed to validate the effectiveness of the revised DSUVIA directions for use)
- IDRA +4.3% (enters into a clinical development support agreement with Pillar Partners Foundation)
- ALNY +3.6% (presents new clinical results for Givosiran)
- INFY +2.9% (rebounding following Friday’s post earnings decline)
- SHPG +2.5% (announces sale of oncology business to Servier for $2.4 bln)
- JD +0.8% (clarifies potential confusion caused by certain statements made by CEO Richard Qiangdong Liu in a recent event)
- GOOG +0.6% (positive article from Barrons), .
- LOXO +6.1% (upgraded to overweight from equal-weight at Morgan Stanley)
- ULTA +2.3% (upgraded to Buy from Neutral at Guggenheim)
- BCS +2% (upgraded to Buy from Hold at Jefferies)
- COST +1.2% (upgraded to Outperform from Market Perform at Wells Fargo)
- AWK +0.7% (upgraded to Buy from Neutral at Janney)
In reaction to disappointing earnings/guidance:
- HCSG -1.7%, (guidance), JBHT -1.3%
- CLDX -45.6% (reports that the randomized Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint)
- WPP -4.8% (announces Sir Martin Sorrell has stepped down as Chief Executive Officer of WPP with immediate effect)
- BPMC -3.5% (reports proof-of-concept data for highly selective RET Inhibitor BLU-667)
- NLNK -3.4% (reports initial data from Phase 1 NLG2105 study )
- CLVS -3.4% (commences separate underwritten public offerings of convertible senior notes and common stock)
- JMEI -2.5% (CFO Yunsheng Zheng resigned effective April 11 for personal reasons)
- HTHT -2.4% (reports blended occupancy rate of 83.7% versus 83.9% last year; reports Q1 blended RevPar of RMB 173 mln versus RMB 152 mln)
- BUD -0.5% (negative article from Barrons)
- KHC -1.2% (downgraded to Underperform from Neutral at Credit Suisse)
- CROX -2.7% (downgraded to Negative from Neutral at Susquehanna)
- SJM -1.1% (downgraded to Underperform from Neutral at Credit Suisse)
- DF -1% (downgraded to Sell from Neutral at Goldman)